Astellas Pharma Inc.;TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
发明人:
SAHIN, UGUR,TÜRECI, ÖZLEM
申请号：
PL14714586
公开号：
PL2976360T3
申请日:
2014.03.17
申请国别(地区):
PL
年份:
2020
代理人:
摘要：
The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well- tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
